EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper

David F Schaeffer, Jennifer Chan, Jason Morin, Marie-Christine Guiot, George M Yousef, Catherine J Streutker iD, Harman Sekhon, Madeline Fitzpatrick, Shakeel Virk, Alexander Wyatt, Alan Spatz iD, Lois Shepherd und 3 weitere

Current Oncology · 09.06.2026 · 33 (6) · 347

DOI: 10.3390/curroncol33060347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, online erschienen am 09.06.2026. Verfasst von David F Schaeffer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Clinical Trials as Topic, Neoplasms. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pathology is foundational to biomarker-driven and translational oncology research, yet systemic barriers limit full pathology engagement in Canadian cancer clinical trials, compromising the tissue-based questions such trials are designed to answer. This commentary and white paper synthesizes the perspectives of a national pathology working group convened at the 2025 Canadian Cancer Trials Group (CCTG) Annual General Meeting with a descriptive internal audit of the CCTG Tumour Tissue Data Repository (TTDR), in which biospecimen attrition was tabulated at the patient level by disease site; no inferential testing was performed. The TTDR data revealed substantial attrition across disease sites, with no tissue submitted for 32–44% of patients and slides submitted in place of formalin-fixed paraffin-embedded blocks for up to 51% of cases, reflecting persistent misalignment between protocol expectations and laboratory capacity. From these observations, five interrelated gaps were identified—in trial design, funding and resourcing, digital pathology infrastructure, academic recognition, and knowledge translation around consent and ethics governance. Five corresponding strategies are proposed to align research demands with pathology capacity, reduce attrition, and strengthen biomarker-driven trials. As a consensus- and experience-driven analysis rather than a systematic review, these recommendations are intended to frame a national conversation and a starting point for prospective evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorClinical Trials as TopicNeoplasmsHumansCanadaTranslational Research, Biomedical

Stichwörter der Autor:innen

Canadian Cancer Trials Groupbiomarkersbiospecimen attritionclinical trialsconsent and ethics governancedigital pathologypathologyprecision oncologytranslational oncologytumor tissue

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of British Columbia and Vancouver General Hospital, Vancouver, BC, Canada.
  • Department of Pathology and Laboratory Medicine, University of Calgary and Arnie Charbonneau Cancer Institute, Calgary, AB, Canada.
  • Department of Pathology and Laboratory Medicine, University of Manitoba and Shared Health Manitoba, Winnipeg, MB, Canada.
  • Department of Pathology, Montreal Neurological Institute and McGill University, Montreal, QC, Canada.
  • Department of Laboratory Medicine and Pathobiology, University Health Network and Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada.
  • Department of Pathology, Unity Health Toronto-St. Michael's Hospital and Department of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada.

ORCID-Profile: Catherine J Streutker, Alan Spatz, Jonathan M Loree, Mary Kinloch

Zitieren

APA

Schaeffer, D. F., Chan, J., Morin, J., Guiot, M. C., Yousef, G. M., Streutker, C. J., Sekhon, H., Fitzpatrick, M., Virk, S., Wyatt, A., Spatz, A., Shepherd, L., Loree, J. M., Kinloch, M., & CCTG Pathology Working Group (2026). Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper. Current Oncology, 33(6), 347. https://doi.org/10.3390/curroncol33060347

Vancouver

Schaeffer DF, Chan J, Morin J, Guiot MC, Yousef GM, Streutker CJ, et al. Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper. Current Oncology. 2026;33(6):347. doi:10.3390/curroncol33060347

BibTeX
@article{Schaeffer2026,
  author = {Schaeffer, David F and Chan, Jennifer and Morin, Jason and Guiot, Marie-Christine and Yousef, George M and Streutker, Catherine J and Sekhon, Harman and Fitzpatrick, Madeline and Virk, Shakeel and Wyatt, Alexander and Spatz, Alan and Shepherd, Lois and Loree, Jonathan M and Kinloch, Mary and CCTG Pathology Working Group, CCTG Pathology Working Group},
  title = {Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper},
  journal = {Current Oncology},
  year = {2026},
  volume = {33},
  number = {6},
  pages = {347},
  doi = {10.3390/curroncol33060347}
}
Kostenlos starten →